Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POD1UM-303/InterAACT 2
2024-512331-72-00Phase 3Completed
- Sponsor
- Incyte
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 13
01
Overview
Phase 3, randomised, double-blind trial in anal squamous cell carcinoma (SCCA) comparing Retifanlimab + carboplatin + paclitaxel with Placebo + carboplatin + paclitaxel (2 arms). Primary endpoint: Progression-free survival. Started Dec 2020; status: completed.
02
Drugs
retifanlimab
03
Conditions
anal squamous cell carcinoma (SCCA)
Beyond the preview
Go deeper on 2024-512331-72-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512331-72-00.